Cargando…

Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer

BACKGROUND: Lenvatinib-pembrolizumab combination (LEAP) is an approved therapy in Japan for advanced endometrial cancer, based on the data from the KEYNOTE-775 clinical trial. We report a case of posterior reversible encephalopathy syndrome (PRES) in a patient who received LEAP therapy for advanced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuura, Yuki, Nishida, Haruka, Kosaka, Takashi, Shigekawa, Kazuyuki, Takasaki, Kazuki, Ichinose, Takayuki, Hirano, Mana, Hiraike, Haruko, Nagasaka, Kazunori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895820/ https://www.ncbi.nlm.nih.gov/pubmed/36741713 http://dx.doi.org/10.3389/fonc.2022.1079716

Ejemplares similares

Validation of an on-chip p16(ink4a)/Ki-67 dual immunostaining cervical cytology system using microfluidic device technology
por: Hashimoto, Kei, et al.
Publicado: (2023)

Serum vascular endothelial growth factor associated with the progression of granulosa cell tumor: a report of two cases
por: Takasaki, Kazuki, et al.
Publicado: (2023)

Effect of Different Educational Interventions on Knowledge of HPV Vaccination and Cervical Cancer among Young Women: A Preliminary Report
por: Takahashi, Yuko, et al.
Publicado: (2022)

Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer
por: Kanda, Ranka, et al.
Publicado: (2018)

Chlamydia Peritonitis Mimicking Juvenile Carcinomatous Peritonitis Diagnosed by Exploratory Laparoscopy: A Case Report
por: Nishida, Haruka, et al.
Publicado: (2023)

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
por: Makker, Vicky, et al.
Publicado: (2020)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy
por: Sasamori, Yukifumi, et al.
Publicado: (2021)

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2022)

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2023)

Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775
por: Yonemori, Kan, et al.
Publicado: (2022)

Ulipristal acetate simultaneously provokes antiproliferative and proinflammatory responses in endometrial cancer cells
por: Kanda, Ranka, et al.
Publicado: (2021)

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
por: Makker, Vicky, et al.
Publicado: (2021)

Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
por: Shen, Sherry, et al.
Publicado: (2021)

Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report
por: Fellouah, Massine, et al.
Publicado: (2023)

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity
por: Staropoli, Nicoletta, et al.
Publicado: (2023)

Combined use of pembrolizumab and lenvatinib: A review
por: Eisinger, Casey, et al.
Publicado: (2023)

Radiation recall dermatitis during treatment of endometrial cancer with pembrolizumab plus lenvatinib: A case report
por: Heisler, Elise, et al.
Publicado: (2023)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
por: Feng, Mingyang, et al.
Publicado: (2022)

Detection of HPV RNA molecules in stratified mucin-producing intraepithelial lesion (SMILE) with concurrent cervical intraepithelial lesion: a case report
por: Fukui, Shiho, et al.
Publicado: (2019)

A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
por: Mehta, Naaman, et al.
Publicado: (2023)

The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-β/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer
por: Fukui, Shiho, et al.
Publicado: (2019)

Loss of the cell polarity determinant human Discs-large is a novel molecular marker of nodal involvement and poor prognosis in endometrial cancer
por: Sugihara, Takeru, et al.
Publicado: (2016)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
por: Hunt, Jonathan T., et al.
Publicado: (2021)

Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells
por: Takeuchi, Makoto, et al.
Publicado: (2019)

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
por: Bedrose, Sara, et al.
Publicado: (2020)

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Lenvatinib plus pembrolizumab a new effective combination of targeted agents
por: Perez-Fidalgo, J.A., et al.
Publicado: (2023)

Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma
por: Tseng, Yu-Ju, et al.
Publicado: (2022)

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China
por: Zheng, Zhiwei, et al.
Publicado: (2022)

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
por: Finn, Richard S., et al.
Publicado: (2020)

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
por: Wu, Chi-Jung, et al.
Publicado: (2022)

Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma
por: Boudin, Laurys, et al.
Publicado: (2022)

The TGF-β/UCHL5/Smad2 Axis Contributes to the Pathogenesis of Placenta Accreta
por: Hashimoto, Kei, et al.
Publicado: (2023)

Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma
por: Osawa, Yoko, et al.
Publicado: (2017)

Automated system for diagnosing endometrial cancer by adopting deep-learning technology in hysteroscopy
por: Takahashi, Yu, et al.
Publicado: (2021)

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
por: Taylor, Matthew H., et al.
Publicado: (2020)

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update
por: Makker, Vicky, et al.
Publicado: (2023)

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
por: Makker, Vicky, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9tviu37l3hhm0ddh99bufevski